Putative antibody-mediated rejection (AMR) in HLAidentical sibling transplantation has rarely been reported and occurred before routine calcineurin inhibitor use. A 29-year-old male developed allograft dysfunction following an HLA-identical renal transplant from his sibling. A pretransplant panel-reactive antibody (PRA) was elevated, pre-transplant crossmatch was negative and no donorspecific antibody (DSA) was identified. Induction with alemtuzumab was followed by maintenance immunosuppression with corticosteroids, tacrolimus and mycophenolate. A biopsy for allograft dysfunction suggested AMR, but DSA could not be detected. Treatment for rejection was transiently successful. Undetectable minor histocompatibility antibodies may have contributed.
Introduction
Transplants from HLA-identical siblings usually result in favourable outcomes [1] . We present a case of allograft failure attributed to antibody-mediated rejection (AMR) following transplantation from an HLA-identical sibling. Although the allograft pathology was consistent with AMR, no donor-specific antibody (DSA) was identified. The patient in this case received his transplant and much of his care at another medical centre but was referred to our institution due to persistent allograft dysfunction.
Case
A 29-year-old man with a history of an undefined renal disease who had progressed over 10 years to endstage disease received a kidney from his sister, an ABOcompatible, HLA-identical sibling. Prior to transplant, the panel-reactive antibody (PRA) was 95% for HLA class I and 14% for class II, B-and T-cell flow cytometric crossmatch testing was negative and DSA was undetectable. He received a standard dose immunosuppression regimen consisting of intraoperative alemtuzumab followed by corticosteroids, tacrolimus and mycophenolate sodium for maintenance. Five years before, he received a transplant from his mother that failed within 1 year, reportedly due to Banff type III acute rejection. No mention of a DSA or positive C4d staining in the allograft at that time was in the records that were available to us.
Although the patient felt well after transplant and did not need dialysis, his renal function did not improve as quickly as expected. On post-operative Day 7, his creatinine was 2.4 mg/dl. A biopsy was performed and surprisingly showed marginated mononuclear cells and neutrophils in peritubular and glomerular capillaries, acute tubular injury and diffuse, bright staining of peritubular capillaries for C4d by immunofluorescence (Figure 1 ). Repeat flow cytometric T-and B-cell crossmatch testing was found to be positive. The findings were consistent with AMR.
Initial treatment for AMR consisted of pulse methylprednisolone, five sessions of plasmapheresis followed by 10 mg/kg intravenous immunoglobulin (IVIG) (Days 9-11) and two doses of rituximab (Days 13 and 30). A repeat biopsy (Day 38) demonstrated mild improvement. Persistent C4d staining prompted the administration of two treatments with 2 g/kg IVIG (Days 45-46). A biopsy performed 10 weeks following transplantation was again compatible with AMR, leading to rituximab treatment and repeat plasmapheresis and IVIG (2 g/kg). Additionally, oral cyclophosphamide replaced mycophenolate sodium.
Two months later, his renal function continued to be poor (creatinine 3.0 mg/dl). The repeat biopsy suggested persistent AMR. This puzzling situation prompted his transfer to our hospital for management. The biopsy findings were unchanged. Cyclophosphamide was replaced with mycophenolate mofetil because of leucopaenia. We confirmed that the donor and recipient were matched at HLA-DP, DQ and C loci, and high resolution typing did not demonstrate any discrepancy. The referring institution had arranged for testing for antibodies against phospholipids, the angiotensin receptor, vimentin, red blood cell antigens and random platelet antigens were negative. Testing for antibodies against major-histocompatibility-complex class Irelated chain A (MICA) was borderline positive but not donor specific. Monocyte crossmatch performed by another medical centre was reported as inconclusive.
The patient was ultimately dismissed from our hospital with improved and stable allograft function (creatinine 2.1 mg/dl) and on standard dose immunosuppression regimen with tacrolimus, mycophenolate mofetil and prednisone. His primary transplant nephrologist resumed care and his immunosuppressive regimen remained the same. Unfortunately, within 3 months, his creatinine increased to 6.7 mg/dl. Histologic evidence of AMR with borderline changes for cellular rejection with patchy interstitial inflammation was demonstrated, but DSA was never detected. He was again treated for AMR, but ultimately maintenance dialysis was needed. Before immunosuppression was tapered, a biopsy was done and revealed severe changes of AMR, with arterial fibrinoid necrosis, diffuse and global mesangiolysis, glomerular and peritubular capillary neutrophils and mononuclear cells. Immunofluorescence demonstrated bright, diffuse C4d staining (Figure 2 ).
Discussion
Renal transplantation from an HLA-identical sibling donor usually results in favourable long-term outcomes [1] . Our patient had an HLA-identical sibling donor, but developed AMR soon after transplant. According to the Banff '07 schema, definitive diagnosis of acute AMR requires histologic features of tissue injury, immunopathologic evidence of antibody (e.g. C4d positivity) and serologic evidence of DSA [2] . Banff criteria for AMR were not met in this case Antibody-mediated rejection following transplantation from an HLA-identical sibling despite clear histologic evidence because of undetectable DSA.
Although the patient had a positive flow crossmatch early post-transplant, the recent exposure to alemtuzumab may have complicated the result. Alemtuzumab is a humanized monoclonal antibody to CD52, an antigen very specific to lymphocytes, monocytes, eosinophils and epithelial cells of the epididymis and seminal vesicle [3] . Alemtuzumab can be recognized as an anti-human antibody and has resulted in false positive cross matches by flow cytometric and complement-dependent cytotoxic techniques [4] .
C4d, a marker of antibody-mediated complement fixation on renal endothelium, was demonstrated on all biopsies in this case. In humans, C4d disappearance from peritubular capillaries has occurred as soon as 8 days following antibody removal [5] . The sensitivity and specificity of peritubular C4d staining for AMR is 95% and 96%, respectively, when serum DSA is used as a rejection criterion [5] . Serologic detection of unusual, non-HLA DSA leading to rejection is limited. As such, this case highlights the limitations of the existing diagnostic criteria for acute AMR.
With recent advances in DSA characterization, MICA antigens, minor histocompatibility antigens (mHA), endothelial cell (EC) antigens and other host-specific antigens have been studied in rejection, but their significance is not well defined. Presensitization with anti-MICA antibodies has been associated with decreased allograft survival [6] . Interestingly, traditional crossmatching techniques are insensitive when MICA antibodies are present because the antigens are not present on peripheral lymphocytes [6] . HLA-identical siblings usually have matched MICA because of the chromosomal location of MICA, and therefore rejection resulting from these antibodies in HLA-identical sibling organ transplantation is unlikely. Tests for MICA antibodies were borderline positive in this patient but not donor specific.
DSA is sometimes not initially identified because testing for antibodies against HLA-DP, DQ and C loci is not routinely performed. These antibodies do not often result in rejection, but it has been reported [7] . In true HLA-identical kidney transplant this should not be a cause. Additionally, the level of antibody may be too low for detection or is absorbed in the allograft and only identified when an allograft nephrectomy is performed [8] . The patient in this case did not have an allograft nephrectomy. We also do not have tissue or serum from the time of his first kidney transplant to look for DSA. Another possibility is the presence of an antibody that we do not have a ligand to.
In HLA-identical sibling organ transplantation, graft rejection more often occurs when recipients have increased parity, prior blood transfusions or previous transplants. Furthermore, these transplants fail more frequently among recipients who have a high PRA suggesting that antibodies against mHA may contribute to rejection [9] . If only HLA-reactive antibodies were important, the PRA would be irrelevant in these transplants. Antibodies to mHA or EC may occur together with anti-HLA resulting in rejection [9] . Interestingly, the recipient in this case had a high PRA.
Putative AMR in HLA-identical sibling transplantation has rarely been reported and occurred before calcineurin inhibitor use. Collins et al. found diffusely positive C4d staining of peritubular capillaries with evidence of tissue injury in 2 of 17 HLA-identical grafts (HLA-A, -B and -C loci) [10] . Serologic analysis was unavailable, but mixed lymphocyte reaction was nonreactive pre transplant.
This case highlights several points. Antibody-mediated damage occurs in HLA-identical sibling organ transplantation receiving a calcineurin inhibitor. The responsible antibodies are presumably against non-HLA antigens and were not detected. Because a subset of DSA is not necessarily detected by current techniques, clinicians should consider AMR if the renal pathology is suggestive even if DSA is not detected. Lastly, false-positive crossmatch testing is possible after using chimeric or humanized monoclonal antibodies.
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